Recruiting

Testing a new cancer treatment for tumors with a specific p53 mutation

Plain-English translation of NCT06778863 on ClinicalTrials.gov ↗ · Source last updated February 2026 · Translation generated June 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This trial is testing a new medication called in patients with advanced cancers that harbor a specific p53 R175H mutation. The medication is designed to work with your immune system to target cancer cells that carry this particular genetic change. Researchers want to find the right dose of this treatment and learn how well it works.

Some cancers have a specific mutation in the p53 gene that makes them harder to treat with standard therapies. This medication is being developed as a targeted approach for patients whose cancers have this particular mutation and have stopped responding to other treatments.

Do you qualify?

You likely qualify if…

you are at least 18 years old
you have advanced or metastatic solid tumors that have progressed after standard treatment or have no standard treatment available
your tumor has been confirmed to carry the p53 R175H mutation by a laboratory test
you are positive for a specific immune marker called HLA-A*02:01
you are in generally good health with adequate organ function (liver, kidneys, and blood counts)

You likely don't qualify if…

you have Li-Fraumeni syndrome or an inherited p53 R175H mutation
you have previously received other p53-directed therapies
you have not recovered from side effects of previous cancer treatments
you currently have an active infection requiring antibiotics or other antimicrobial treatment
you have active cancer in your brain or cancer that has spread to the membranes around your spinal cord

What participation looks like

The trial has two parts: first, doctors will gradually increase the dose of the medication to find the safest and most effective dose, then they will expand the study to give more patients that dose to see how well it works. You will receive the medication and have regular visits for blood tests, scans, and check-ups to monitor how your body responds and how your cancer is changing. The study will track your safety, how your body processes the medication, and whether your tumor shrinks or stops growing.

AI-generated summary from trial data · Jun 7, 2026 · Not medical advice

Trial locations(21 sites)

United States

HonorHealth Research Institute, Scottsdale, Arizona

The University of Arizona Cancer Center, Tucson, Arizona

USC - Norris Comprehensive Cancer Center, Los Angeles, California

University of California Davis Comprehensive Cancer Center, Sacramento, California

University of California San Francisco, San Francisco, California